Posts by Immunexpress

Immunexpress Receives Notice of U.S. Patent Allowance for SeptiCyte™ Technology to Quantify Biomarkers

Immunexpress.com

The allowance complements the Company’s growing patent portfolio of gene technology in the detection of host response to sepsis SEATTLE, July 26, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, “Validating biomarker measurement,” which relates to methods…

Read More

Immunexpress Continues Executive Team Expansion with Addition of Fayyaz Memon as VP of Regulatory Affairs & Quality

Immunexpress.com

SEATTLE, July 10, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company’s Executive Team as Vice President of Regulatory Affairs and Quality. “Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences industry,” Rolland D. Carlson, PhD, President…

Read More

SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

Immunexpress.com

SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III…

Read More

SeptiCyte™ LAB Differentiates Sepsis from Infection-Negative Systemic Inflammation in Critically Ill Children

Immunexpress.com

Results of a Pilot Study of SeptiCyte™ LAB in the Pediatric Setting Published in Critical Care Medicine SEATTLE, Sept. 22, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today the publication, in Critical Care Medicine, of data demonstrating the ability…

Read More

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ LAB

Immunexpress.com

SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the upcoming American Thoracic Society International…

Read More

European Society for Intensive Care Medicine

European Society for Intensive Care Medicine October 1-5, 2016 Milan, Italy. Dr Mahdad Noursadeghi, of University College London presented preliminary results in a validation trial of an Immunexpress developed signature for the diagnosis of bacterial infection in patients presenting to ER, and for a second signature in the same validation cohort for differentiating bacterial from…

Read More

36th International Symposium on Intensive Care and Emergency Medicine

36th International Symposium on Intensive Care and Emergency Medicine March 15-18, 2016 Brussels, Belgium. Russ Miller, of Intermountain Healthcare presented data on the market need for accurate sepsis diagnostics using results from the IXP VENUS trial showing that expert physicians agree on a diagnosis of sepsis in between 60 to 80% of cases, highlighting the…

Read More

Revolutionary Diagnostic SeptiCyte™ LAB Cleared By FDA for Suspected Sepsis Patients

Immunexpress.com

SEATTLE, Feb. 22, 2017 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis) from infection-negative (SIRS) systemic inflammation…

Read More

Four-Biomarker Signature Differentiates Viral and Non-Viral Causes of Systemic Inflammation

Immunexpress.com

Results from an investigation of over 40 datasets published in Scientific Reports SEATTLE, June 6, 2017 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced the publication, in Scientific Reports, of data demonstrating the ability of a four-biomarker blood signature to discriminate viral…

Read More